IBRX ImmunityBio, Inc. Common Stock : Bullish and Bearish Analyst Opinions

The tweet expresses sympathy regarding a tragic event while mentioning tickers without providing a financial outlook.

Neuner mentions he told people to invest in ImmunityBio (IBRX) because they "may have just found a cure for cancer." He uses this to illustrate the necessity of a strong "Why" for investing. Unlike Bitcoin's currently muddied narrative, a biotech breakthrough offers a clear, compelling reason for capital allocation. LONG based on the "strong narrative" thesis. Clinical trial failures or regulatory rejections (standard biotech binary risk).

The stock is undervalued because its price has not yet reflected the company's positive clinical progress.

The speaker states a "Gamma squeeze incoming" for IBRX. A gamma squeeze is a rapid price increase driven by market makers hedging their short gamma exposure from sold call options. As the stock price rises, they must buy more shares, pushing the price even higher in a feedback loop. The user is extremely bullish on IBRX in the very short term, anticipating a rapid, options-driven price surge. Gamma squeezes are speculative, difficult to time, and can fail to materialize. If the expected buying pressure doesn't occur, the stock could fall, and any options purchased would lose value rapidly.